Teva has entered into an agreement with Yissum, the Hebrew University of Jerusalem technology transfer company, to finance a yeast-based drug discovery technology developed by Jexys, a Yissum subsidiary. This early investment highlights Teva’s confidence in the technology and supports Teva’s efforts to boost its activity within proprietary drug development.